Latest KFF Health News Stories
Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
People With Down Syndrome Are Living Longer, but the Health System Still Treats Many as Kids
The median life expectancy for a U.S. baby born with Down syndrome jumped from about four years in 1950 to 58 years in the 2010s. That’s largely because they no longer can be denied lifesaving care, including surgeries for heart defects. But now, aging adults with Down syndrome face a health system unprepared to care for them.
La empresa farmacéutica que prosperó sin crear ni un solo medicamento
Aunque Horizon afirma que ahora tiene 20 fármacos en desarrollo, en sus 15 años de existencia aún no ha obtenido la licencia de un producto de su creación.
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
Feds Launch Criminal Investigation Into ‘AGGA’ Dental Device and Its Inventor
KFF Health News and CBS News recently reported that multiple lawsuits allege the device has led to grievous injuries to patients’ mouths, resulting in loss of teeth.
As Montana’s Mental Health Crisis Care Crumbles, Politicians Promise Aid
One of Montana’s largest mental health providers has ratcheted back services amid financial troubles, leaving a vacuum. State policymakers have promised more money to aid behavioral health care, but lasting change could be years out.
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members’ professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
No-Cost Preventive Services Are Now in Jeopardy. Here’s What You Need to Know.
A federal judge’s recent ruling on the Affordable Care Act is by no means the final word. Even parsing its impact is complicated. Here are key issues to watch as the case works its way through the legal system.
KFF Health News' 'What the Health?': The ‘Unwinding’ of Medicaid
As of April 1, states were allowed to begin reevaluating Medicaid eligibility for millions of Americans who qualified for the program during the covid-19 pandemic but may no longer meet the income or other requirements. As many as 15 million people could lose health coverage as a result. Meanwhile, the Medicare Hospital Insurance Trust Fund is projected to stay solvent until 2031, its trustees reported, taking some pressure off of lawmakers to finally fix that program’s underlying financial weaknesses. Alice Miranda Ollstein of Politico, Rachel Roubein of The Washington Post, and Amy Goldstein of The Washington Post join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Daniel Chang, who reported the latest KHN-NPR “Bill of the Month” feature about a child not yet old enough for kindergarten whose medical bill landed him in collections.
States Step In as Telehealth and Clinic Patients Get Blindsided by Hospital Fees
At least eight states have implemented or are considering limits on what patients can be billed for the use of a hospital’s facilities even without having stepped foot in the building.
Minnesota Overhauled Substance Use Treatment. Rural Residents Still Face Barriers.
A recent policy change in Minnesota promotes quick evaluations and care for people with substance use disorders. But because of gaps riddling rural treatment systems nationwide, the promise of swift care isn’t reaching rural Minnesotans.
FDA Evaluates ‘Safety Concerns’ Over Dental Devices Featured in KHN-CBS Investigation
A KHN and CBS News investigation found that a dental appliance called the AGGA has been used by more than 10,000 patients, and multiple lawsuits allege it has caused grievous harm to patients.
La decisión podría afectar los exámenes de detección sin copago y servicios preventivos similares que la mayoría de los estadounidenses con seguro tienen como parte de sus planes de salud.
Judge’s Decision Would Make Some No-Cost Cancer Screenings a Thing of the Past
A U.S. District Court ruling overturned the section of the Affordable Care Act that makes preventive health services — from colonoscopies to diabetes screenings and more — available at no cost to consumers.
States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection
Pharmaceutical companies have put the brakes on many states’ ability to execute prisoners using lethal injections. Lacking alternatives, states are trying to keep the public from learning details about how they carry out executions.
A Progress Check on Hospital Price Transparency
Hospitals are facing mixed reviews regarding their efforts to comply with a federal requirement that they post information about prices related to nearly every health care service they provide.
Congressman Seeks to Plug ‘Shocking Loophole’ Exposed by KHN Investigation
A federal lawmaker has introduced a House bill that would close one of a laundry list of oversight gaps revealed in a recent KHN investigation of the system regulators use to ban fraudsters from billing government health programs, including Medicare and Medicaid.
Banning Noncompete Contracts for Medical Staff Riles Hospitals
It’s about the money — on both sides — as arguments swirl about patient safety, rising prices, and paying back on-the-job training.
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.
